The Department of Health and Human Services (HHS) Office of the Inspector General (OIG) released an evaluation examining how vertical integration in Medicare Part D affects sponsor drug costs, pharmacy reimbursement, and enrollee cost sharing. The review was prompted by growing concerns regarding the concentration of the Part D market among vertically integrated organizations that combine Part D sponsors, pharmacy… (Eisen, May 20, 2026) #Medicare Part D, #Prescription Drugs